Researchers are continually evaluating the autoimmune diseases primary sclerosing cholangitis and primary biliary cholangitis and their effects on bile duct inflammation and liver damage. Some of the latest studies demonstrated that obeticholic acid improved GLOBE scores in PBC and relieved pruritus symptoms in PSC. Other recent reports include discussion of a novel PSC patient-reported outcome tool, cases of hepatitis E found among patients with PSC and inflammatory bowel disease, and demographic risk factors.
To read the full story, visit: Healio
New study evaluates efficacy of PET imaging to manage chronic liver diseases
EASL governing board announces new Vice-Secretary
A web-based program is as effective as group counseling for patients with non-alcoholic fatty liver disease